Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low ris...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Karl-Ulrich Petry, Kaatje Bollaerts, Paolo Bonanni, Margaret Stanley, Rosybel Drury, Elmar Joura, Susanne K. Kjaer, Chris J. L. M. Meijer, Didier Riethmuller, Benoit Soubeyrand, Pierre Van Damme, Xavier Bosch
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Taylor & Francis Group 2018-07-01
Серія:	Human Vaccines & Immunotherapeutics
Предмети:	human papillomavirus cervical cancer vaccination human papillomavirus recombinant vaccine nonavalent types 6, 11, 16, 18, 31, 33, 45, 52, 58, modelling
Онлайн доступ:	http://dx.doi.org/10.1080/21645515.2018.1450125
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Схожі ресурси